*Nanotechnology Perceptions*
*ISSN 1660-6795*
*www.nano-ntp.com*

# Exploring the Treatment of Intracranial Germinoma: Leveraging Emerging Trends in Nanotechnology for Enhanced Diagnosis and Therapy

**Dr. Maria Gabriela D. Gonzales**

*Western Mindanao State University Zamboanga City, Philippines*

**Abstract**
Primary intracranial germ cell tumors (ICGCTs) are rare, accounting for less than 1% of all central nervous system (CNS) cancers. Germinoma, the most common subtype, is an aggressive tumor that primarily affects males aged 10 to 21 years, typically in midline brain structures such as the pineal and suprasellar regions. The clinical triad of visual disturbances, diabetes insipidus, and panhypopituitarism is common in tumors located in the suprasellar region, due to their proximity to the hypothalamus and pituitary gland.Treatment for intracranial germinomas generally includes a combination of radiation, chemotherapy, and surgery to reduce tumor size and prevent recurrence. However, these conventional treatments often lead to long-term side effects, including cognitive impairments, endocrine disorders, and neurological deficits, severely affecting patients' quality of life. Alongside tumor management, addressing endocrinopathies through hormone replacement therapy is crucial. Despite these interventions, the prognosis for patients with β-HCG-secreting tumors remains challenging, underscoring the need for more targeted therapies. Recent advancements in nanotechnology and targeted drug delivery systems show promise in improving treatment precision, minimizing side effects, and enhancing outcomes. Further research is necessary to refine these emerging therapies and develop personalized approaches to improve patient care and survival rates.

**Keywords:** Intracranial Germinoma, Trends in Nanotechnology, Enhanced Diagnosis, Therapy, Case Report

## 1. Introduction

Intracranial germinomas, a subtype of primary intracranial germ cell tumors (ICGCTs), are rare and aggressive tumors predominantly affecting children and young adults. These tumors typically present in midline brain structures such as the pineal and suprasellar regions, causing neurological deficits and endocrine dysfunction. Germinomas account for the majority of ICGCTs, but their treatment remains challenging due to the potential for recurrence and the significant side effects associated with conventional therapies. Traditional management involves a combination of surgery, radiation, and chemotherapy, but these approaches are often associated with long-term complications such as cognitive impairment, hormonal disturbances, and neurological deficits (Kubo et al., 2016). As such, new strategies to enhance the precision of diagnosis and reduce the harmful effects of treatment are critically needed.

Jennings, Gelman & Hochberg (1985) defined primary intracranial germ cell tumors as rare, accounting less than 1% of all CNS malignancies. Germinomas, the most common subtype, are mmalignant but have a relatively benign overall prognosis. As many as 10% of

Germinomas secrete B-HCG which is associated with the worst clinical outcome (Inamura, Nishio & Ikezaki, 1999). Males are affected more than females and 70% are discovered in ages 10-21 years old. Germinomas manifest a variety of clinical signs and symptoms based on their location. Tumors located in the suprasellar regions are associated with the classic triad of visual symptoms, diabetes insipidus and panhypopituitarism (Rich TA, Cassady JR, Strand RD, et al, 1985).

Endocrine work up should include blood and urine studies for Diabetes Insipidus, hypogonadism, hypothyroidism, secondary adrenal insufficiency, hyperprolactinemia and any evidence of pituitary dysfunction. The overall treatment of Germinoma involves radiation, chemotherapy, surgery and medical management of endocrinopathies. This is the first reported case of Intracranial Germonima in our institution. Likewise, a literature search revealed no similar case ever been reported in the Philippine Literature. As a result, researchers have increasingly turned their attention to more targeted approaches that can minimize these risks while enhancing therapeutic outcomes.

Nanotechnology, with its ability to manipulate matter at the molecular and atomic scale, offers promising solutions for improving both the diagnosis and treatment of intracranial germinomas. Nanomaterials such as nanoparticles, nanorobots, and targeted drug delivery systems can potentially revolutionize current therapeutic practices by enabling more targeted and efficient drug delivery to tumor sites. By crossing the blood-brain barrier and delivering chemotherapeutic agents directly to the tumor, nanotechnology could increase the concentration of drugs at the site of action, thereby improving therapeutic efficacy while minimizing side effects (Zhao et al., 2019). Additionally, nanomaterials can enhance imaging techniques, such as MRI and PET, to detect tumors at earlier stages, allowing for prompt diagnosis and better monitoring of therapeutic responses (Liu et al., 2018).

Recent research has demonstrated the potential of nanotechnology to transform the management of brain tumors, including germinomas, by improving diagnostic accuracy and treatment precision. However, significant challenges remain, particularly in evaluating the safety and long-term effects of nanomaterials in human tissues. Despite these hurdles, ongoing studies suggest that nanotechnology may help overcome the limitations of conventional therapies, offering a more effective and less invasive treatment approach. As advancements in nanomaterial engineering and molecular biology continue, it is likely that these innovations will play a crucial role in shaping the future landscape of intracranial germinoma treatment (Rana et al., 2020). Further research is necessary to refine these technologies and explore their clinical applications in the context of rare but aggressive brain tumors.

**The Case**

This is a case of a 21 year old male, who complained of blurring of vision in the bitemporal area two months prior to admission. This was associated with occasional headache, polyuria and polydipsia with predilection to drinking cold water. Patient likewise complained of constipation, easy fatigability and erectile dysfunction. No history of intake of prohibited drugs, alcohol abuse or history of head trauma.

One month prior to admission. polyuria persisted amounting to approximately 3-9 liters/day. Due to deterioration of visual symptoms now associated with blurring of entire visual field, patient sought consult with an ophthalmologist. A Magnetic Resonance Imaging of the brain was done which revealed infundibullar and suprasellar enhancing mass lesion with mass effect on the optic chiasm [Figure 1]. Patient at this point refused admission.

**FIGURE 1**

Sagittal View : exerting mass effect on the optic chiasm



Coronal View: 25x29x26 mm lobulated suprasellar mass lesion with calcification

It was not until one week PTA when patient noticed progressive loss of vision, unable to identify person and object, and only recognized shadows that prompted the patient to seek admission. Neurosurgery was contemplated and was then referred to endocrine service for evaluation. Patient was examined awake, conscious and coherent with stable vital signs. Fundoscopic evaluation revealed good range of motion, clear media, distinct disk border, pale optic disk, 2:3 AV ratio with no hermorrhage nor exudates. Neuro-Ophthalmologic Examination was negative except for poor visual acuity of both eyes with only hand movement on the right eye.

Patient did not reveal any hyperpigmentation nor was there any palpable thyroid gland and had good muscle strength. Examination of the external genitalia was unremarkable, with an estimated 15 grams bilateral testicular volume.

Endocrine work up revealed the following values: Luteinizing Hormone of 0.20 iu/L (2-12 iu/L) ; Testosterone level of 1.960 ng/ml (2.8-8 ng/ml); a low AM cortisol 3.10 ug/dl (5-18 ug/dl); and a low PM cortisol of l ug/dl ( 2-13 ug/ml); a subnormal FT4 of 3.79 ng/dl (4.5-12 ng/dl) with a low TSH value of 3.l9 mU/L (0.32-5 mU/L) and a high Prolactin level of 49.68

ng/ml (1.61-18.77 ng/ml). Biochemical evaluation is consistent with Panhypopituitarism, with hyperprolactinemia due to pituitary stalk compression secondary to the tumor mass.

Prior to surgery, our patient's hourly urine output averaged 150-300 cc with average Urine Specific Gravity of 1.002, equivalent to 50 mOsm/Kg. Patient was awaken an average of 6-8x at night due to nocturia. Vigilant fluid replacement was advised. Pre-operatively, steroid coverage of Dexamethasone 5mg IV every 6 hours was given by the surgical service to decrease inflammation but also sufficed for coverage of patient's secondary adrenal insufficiencyCraniotomy and biopsy of the optic nerve tumor was performed. Intra-operative . findings revealed the tumor noted within the optic nerve with histopathologic findings of Intracranial Germinoma.

Patients' course in the ward was unremarkable except in the 3rd post-op day when patient was admitted in the ICU due to Pneumonia necessitating mechanical ventilation. Sputum Culture grew Streptococcus Pneumoniae which was sensitive to Cefepime. Close monitoring of patient's input to balance patients urine output was achieved with Intravenous fluids. Desmopresin was given based on patient's urine output, serum sodium and urine specific gravity. Patient was extubated on the second ICU day and was transferred to regular ward on methylprednisolone, desmopressin and thyroid hormone replacement. Patient was reffered to Oncology service for planned Chemotherapy and Radiotherapy. Additional laboratory evaluation for prognostication was done which revealed an alfa feto protein level of 4.52 ng/ml (0-15 ng/ml) and positive Beta HCG of 211.27 mIu/ml.

## 2. Methodology

### Study Design

This study is a descriptive case report aimed at providing an in-depth examination of a single patient presenting with clinical manifestations suggestive of an intracranial germinoma. The focus is on detailing the patient's symptoms, diagnostic process, treatment regimen, and outcomes, with particular attention to the diagnostic challenges, therapeutic approaches, and clinical course. As a case report, the objective is to highlight unique aspects of the patient's presentation and response to treatment, while contributing to the existing literature on intracranial germinomas.

### Study Setting

The study was conducted in one of the university Hospitals in the Philippines, a reputable tertiary healthcare facility known for its diagnostic and therapeutic capabilities in neurology, endocrinology, and neurosurgery. The hospital provides a wide range of diagnostic tools, including imaging technologies like MRI and CT scans, as well as laboratory tests, to support the evaluation and treatment of patients with complex neurological and endocrine disorders. The setting will allow for a comprehensive assessment of the patient's medical history, clinical presentation, and response to the treatment plan.

### Study Population

The study focuses on a 21-year-old male patient who presented with the classic triad of bitemporal hemianopsia, diabetes insipidus, and panhypopituitarism—clinical signs suggestive of a midline brain tumor, likely located in the suprasellar region. The patient's medical history, including the onset and progression of symptoms, laboratory findings, and imaging results, was carefully documented. These clinical manifestations, often associated with intracranial germinomas, will serve as the basis for diagnosing the condition and guiding the treatment strategy. The patient's case will be presented in detail, with a focus on diagnostic imaging (e.g.,

MRI findings), hormonal assays, and the multidisciplinary approach used for treatment and management.

**Data Collection**

Data was collected through the patient's medical records, clinical examinations, diagnostic imaging reports (such as MRI scans), hormonal tests, and surgical or biopsy reports if available. The study will also include a detailed review of the patient's clinical progression, including the response to treatment (radiation, chemotherapy, and/or surgery), follow-up evaluations, and any adverse effects observed. The goal was to provide a comprehensive narrative of the patient's journey from diagnosis to treatment and recovery.

**Ethical Consideration**

Ethical considerations in medical research are critical to ensuring the protection of participants, maintaining scientific integrity, and promoting trust in the research process. Some key ethical principles were observed by the researcher:

**Informed Consent:** The patient was fully informed about the nature, purpose, risks, and benefits of the research. He voluntarily agree to participate without coercion, and was given the right to withdraw at any time.

**Confidentiality and Privacy:** Researchers ensured the privacy of participants and safeguard any personal or sensitive data. Patient identities and medical information remained confidential unless consent is given for sharing.

**Minimizing Harm:** Research should aim to minimize potential harm, discomfort, or risk to participants. Researcher prioritized the safety and well-being of participants throughout the study.

**Beneficence and Non-Maleficence:** Researchers aimed to maximize the benefits of the research while minimizing harm. It ensured that the potential benefits of the study outweigh any risks to participants.

**Scientific Integrity:** Researcher maintained honesty and transparency in her work. This includes proper reporting of results, acknowledgment of sources, and avoidance of manipulation or falsification of data.

**Risk Assessment:** Ethical medical research requires thorough risk assessment. If there are any known risks, it was disclosed to participant, and the research proceeds only if those risks are deemed acceptable.

**Approval from Ethics Committees:** All medical research must be reviewed and approved by an Institutional Review Board (IRB) or Ethics Committee to ensure compliance with ethical standards and regulations.

**Vulnerable Populations:** Special care was taken when involving vulnerable population ensuring that their participation is not exploitative and that they are fully protected.

**Post-Study Obligations:** Researcher will provide post-study care, especially if the study involves medical interventions. The patient was also informed about the study's outcomes or results when appropriate.

## 3. Discussion

Russel & Rubenstein (1984) described germinomas as malignant tumors thought to originate from neoplastic transformation of embryonic Germ cell that failed to migrate out of the CNS during development. The underlying etiology remains unknown. Generally, germinomas are diseases of children and adolescents. Of these tumors, 70% occur in persons aged 10-21 years old. Typical clinical findings of visual deficits, diabetes insipidus and hypopituitarism in a young patient are highly suggestive of Germinoma. However, one must perform further laboratory and radiologic tests to ensure the diagnosis.

Our patient was diagnosed at the age of 21 years of age. Initial tumor symptoms included deficits of visual acquity, bitemporal hemianopsia and diabetes insipidus consistent with the triad of symptoms suggestive of a Suprasellar tumor. Our patients MRI of the brain revealed a huge lobulated mass lesion such that the optic chiasm was compressed. [Figure 3] It is said that up to 35% of patients with suprasellar tumors can be asymptomatic for more than 6 months, and in this subgroup of patients, the time between first symptom and diagnosis may be prolonged Pomarede (Czernichow & Finidori et al, 1982).

The presence of diabetes insipidus is due to the destruction of the neurohypophysis due to a pituitary tumor. This diagnosis however should be made in the absence of hyperglycemia and a normal kidney function. Our patient is a non diabetic and had a normal serum creatinine of 1.02 mg/dl. Diagnosis of Diabetes Insipidus is made clinically and laboratory findings can provide the confirmation. Our patient had predominant symptoms of polyuria, polydipsia, nocturia and had predilection to drinking cold liquids. A urine specific gravity of 1.005 or less and a urine Osmolality less than 200 mOsm/Kg are the hallmarks of Diabetes Insipidus.

Endocrine work-up should involved hormonal evaluation for hormonal excess and hormonal defiency, to provide basis for management of pituitary dysfunction accordingly prior to planned neurosurgery. Our endocrine workup included a low serum LH (0.20 iu/L) and low Testosterone level (1.960 ng/ml), suggestive of secondary hypogonadism. Cortisol oscillates in a 24 hour circadian rhythm with cortisol level being at its highest in the morning just before waking up (6am) lowest in the evening (12 midnight). The absence of diurnal pattern in our patient, with low AM cortisol (3.10ug/dl) and PM cortisol (l ug/dl) is consistent with hypoadrenalism. Likewise, a low FT4 (3.79 ng/ml) and a low TSH (3.19mU/L) are values consistent with secondary thyroid dysfunction. Our patient had an elevated prolactin level (49.68 ng/ml) and in the presence of a Macroadenoma, this hyperprolactinemia is obviously secondary to pituitary stalk compression.
Bruce, Connoly & Stein (1995) stated that surgical intervention is the treatment of choice in this particular case due to the huge tumor mass causing mechanical and biochemical abnormalities, however, the primary role of surgery is to obtain tissue for histologic identification. Germinomas are extremely radiosensitive. Systemic craniospinal irradiation is likewise recommended because these fast growing tumors have a marked tendency to spread via the Cerebrospinal fluid. Chemotherapy is traditionally reserved for salvage therapy in those tumors who are not responding to initial radiation therapy.

The diagnosis of Germinoma must be established histologically (Baumgartner, 1992) Intracranial germinomas are histologically similar to gonodal seminoma. The rarity of Intracranial Germinoma is the rate limiting factor in the phase of clinical research such that at present, there has been no clear-cut therapeutic management consensus. Part of Germinoma

work-up is obtaining the AFP and B-HCG. The presence or absence of specific tumor markers secreted by tumor cells has been an extremely important adjunct in the diagnosis of Germ Cells tumors (Acevedo, Tong & Hartstock, 1995).

A mild elevation of B-HCG has been noted in the synctioblastic form of Germinoma (Shinoda, Yamada & Sakai et al., 1988). The low level of B-HCG (211.27 mlu/ml) in our patient may be an non-specific marker of malignancy. These tumor markers are measured for diagnostic purposes, monitoring response to therapy and detecting early signs of tumor recurrence.

Packer, Sutton & Rosenstock (2002) defined that prognosis of germinoma is generally very good with a five year survival rate of 95% in patients who received more aggressive treatment. Long tern follow-up with neuroimaging is recommended approximately every 6-12 months for several years. Likewise, biochemical evaluation to determine dossage of hormone replacement should be carefully monitored.

## 4. Conclusion

This paper is the first case ever reported in the Philippine Literature of a patient presenting with classic triad of symptoms of polyuria, visual abnormality and panhypopituitarism in a setting of a huge suprasellar tumor diagnosed histologically as Intracranial Germinoma. Although prognosis is good, endocrine dysfunction should be sought and manged appropriately to affect a better clinical outcome and quality of life. Intracranial Germinoma is a rare but important differential diagnosis for patient presenting with bitemporal hemianopsia, Diabetes Insipidus and hypopituitarism. Our patient is the first reported case of Intracranial Germinoma in our institution and no similar reported case has been published in the Philippine literature.

## 5. Reference

[1] Acevedo HF, Tong JY, Hartstock RJ, Human Chorionic Gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origin. Canmcer 1995; 76:1467-1475.
[2] Baumgartner JE, Edwards MSB: Pineal tumors. Neorosurg Clin North Am 3:853-862,1992
[3] Bruce, JJ, N., Connoly., & stein, B.M. (1995). Pineal cell and Germ cell tumors. In A.H. Kaye & E.R laws (Eds), Brain tumors (pp725-755). Edinburgh: Churchill Livingstone.
[4] Inamura T, Nishio S, Ikezaki K et al. Human Chorionic Gonadotropin in the CSF, not serum predicts outcome in Germinoma J Neurol Neurosurg Psychiatry 1999;66:654-657
[5] Jennings MT, Gelman R, Hochberg F: Intracranial germ-cell tumors: Natural history and pathogenesis. J Neutosurgery 63:155-167, 1985
[6] Kubo, O., et al. (2016). "Treatment of Germinoma: A Review of Current Concepts and Challenges." Journal of Neurosurgery, 125(1), 15-23
[7] Liu, Z., et al. (2018). "Nanotechnology in Cancer Diagnosis and Therapy: A Review." Chinese Journal of Cancer Research, 30(4), 343-358.
[8] Packer RJ, Sutton LN, Rosenstock JG et al. Pineal region tumors of childhood Pediatrics 1:74:97-102.
[9] Pomarede R, Czernichow P, Finidori J et al. Endocrine aspects and tumoral markers in tracranial germinoma: an attempt to delineate the diagnostic procedure in 14 patients. J Pediatr 1982; 101:374-378.
[10] Rana, S., et al. (2020). "Emerging Applications of Nanotechnology in the Treatment of Intracranial Tumors." Journal of Nanomedicine & Nanotechnology, 11(5), 305-312.
[11] Rich TA, Cassady JR, Strand RD, et al: Radiation therapy for pineal and suprasellar germ cell tumors. Camncer 55:932-940,1985
[12] Russel DS, Rubenstein Lj. Pathology of Tumors of the Nervous System Baltimore: Williams and Wilkins, 1984.
[13] Shinoda J, Yamada H, Sakai N et al. Placental alkaline phosphatase as tumor marker for primary intracranial germinoma. J Neurosurg 1988; 68:710-720.
[14] Zhao, M., et al. (2019). "Nanoparticles for the Targeted Delivery of Therapeutic Agents for Brain Tumors." Pharmaceutical Research, 36(3), 1-13.